XML 18 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 4,762 $ 59,640
Short-term investments 291,370 329,462
Accounts receivable, net of allowance of nil at December 31, 2017 and 2016 5,014 15,678
Inventory 10,726 11,109
Other current assets 14,948 10,063
Total current assets 326,820 425,952
Long-term investments 57,088 0
Property, plant and equipment, net 47,463 65,601
Goodwill 76,501 76,501
Other assets 994 817
Total assets 508,866 568,871
Current liabilities:    
Accounts payable 4,782 2,816
Accrued compensation 8,263 18,280
Accrued clinical trial expenses 9,461 7,958
Other accrued expenses 10,064 4,711
Interest payable 4,198 4,198
Liability related to refundable upfront payment 0 12,500
Deferred revenue, current portion 18,949 14,352
Other current liabilities 446 7,407
Total current liabilities 56,163 72,222
Senior secured notes, net 245,207 243,464
Liability related to the sale of future royalties, net 94,655 105,950
Deferred revenue, less current portion 19,021 51,887
Other long-term liabilities 5,992 7,223
Total liabilities 421,038 480,746
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2017 or 2016 0 0
Common stock, $0.0001 par value; 300,000 shares authorized; 159,524 shares and 153,212 shares issued and outstanding at December 31, 2017 and 2016, respectively 15 15
Capital in excess of par value 2,207,865 2,111,483
Accumulated other comprehensive loss (2,111) (2,363)
Accumulated deficit (2,117,941) (2,021,010)
Total stockholders’ equity 87,828 88,125
Total liabilities and stockholders’ equity $ 508,866 $ 568,871